-
Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts?
Monday, November 13, 2017 - 12:23pm | 401Read More...Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...
-
What's Coming For Large-Cap Pharma Stocks This Earnings Season?
Wednesday, July 22, 2015 - 4:13pm | 438Read More...Q2 earnings season for large-cap pharmaceutical stocks is set to kick off when Eli Lilly and Co (NYSE: LLY) reports results on Thursday morning. Piper Jaffray analyst Richard Purkiss released a report this week outlining what the market can expect once the action begins on Thursday. Peak Forex...
-
The Note Moving Pharma Giants Today
Wednesday, June 17, 2015 - 4:06pm | 561Read More...Large-cap pharmaceutical companies will see revenue growth hit a peak during 2016 and 2017, followed by a wave of patent expirations in the closing three years of the current decade, an analyst said Monday. "Investors should consider protecting their portfolios against a sector de-rating" that...
-
LLY Issues Disappointing Long Term Guidance
Friday, December 11, 2009 - 1:05pm | 108Read More...Analyst Richard Purkiss of Atlantic Equities maintain his “underweight” rating on Eli Lilly (NYSE: LLY). The target price for LLY is set to $31. Eli Lilly has issued its 2010 guidance inline with expectations. However, its guidance for 2012-2014 was disappointing. Many of the company’s patents are...
